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Abstract
Matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) allows the identification of
microorganisms directly from positive blood culture broths. Use of the MALDI-TOF MS for rapid identification of
microorganisms from blood culture broths can reduce the turnaround time to identification and may lead to earlier
appropriate treatment of bacteremia. During February and April 2010, direct MALDI-TOF MS was routinely performed on all
positive blood cultures. During December 2009 and March 2010 no direct MALDI-TOF MS was used. Information on
antibiotic therapy was collected from the hospital and intensive care units’ information systems from all positive blood
cultures during the study period. In total, 253 episodes of bacteremia were included of which 89 during the intervention
period and 164 during the control period. Direct performance of MALDI-TOF MS on positive blood culture broths reduced
the time till species identification by 28.8-h and was associated with an 11.3% increase in the proportion of patients
receiving appropriate antibiotic treatment 24 hours after blood culture positivity (64.0% in the control period versus 75.3%
in the intervention period (p0.01)). Routine implementation of this technique increased the proportion of patients on
adequate antimicrobial treatment within 24 hours.
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Introduction
Bloodstream infections are associated with high rates of
morbidity and mortality and microbiological identification of
causative pathogens is crucial for optimal management[1].
However, conventional identification is based on time-consuming
procedures, and species identification and susceptibility testing
usually requires at least 48 hours after blood cultures become
positive.
Developed in the 1980s [2,3], the MALDI technique is an
ionization technique that allows the analysis of biomolecules.
Ionized biomolecules are accelerated in an electric field, and
different molecules are separated according to their mass to charge
ratio. The method is used for detection and characterization of
biomolecules with molecular masses between 400 and
350,000 Da. The feasibility of MALDI-TOF MS identification
of bacterial colonies from solid media has been assessed on a wide
array of clinically relevant bacterial strains as well as yeast isolates.
Correct identification at the species level is obtained in 80–95% of
bacterial isolates [4], and in 66–87% when applied directly on
positive blood culture broths [5–8].
Faster identification of microorganisms causing bacteremia
could allow appropriate species-specific therapy to be started
sooner, thereby improving patient outcome and reducing potential
development of resistance and possible side effects [9]. Direct
application of MALDI-TOF MS on blood culture broth samples
after growth identification of automated culture methods (such as
the Bactec 9240 system (Becton-Dickinson, Sparks, USA)) might
allow earlier implementation of appropriate antimicrobial treat-
ment, but has not been investigated in real-life settings. The aim of
this prospective clinical trial was to assess the impact of performing
direct MALDI-TOF MS on positive blood cultures on turnaround
time and antimicrobial management in patients with bloodstream
infections.
Methods
Study design
The study was conducted between December 2009 and April
2010 in the University Medical Center Utrecht. Direct MALDI-
TOF MS was routinely performed on all consecutively positive
blood cultures during February and April 2010, and standard care
procedures were used in December 2009 and March 2010. In
January 2010, technicians were trained in performing direct
MALDI-TOF MS analysis. Direct MALDI-TOF MS was
performed twice daily on weekdays and once daily during
weekends. All episodes of positive blood cultures, based on alerts
of the Bactec 9240 system, were included. One episode included
all positive blood cultures with the same pathogen(s) within one
week in one patient. Cultures were defined as contaminated if
Coagulase-negative staphylococci or other cutaneous flora was
cultured and not considered clinically relevant by the treating
physician. Susceptibility testing was performed using the Phoenix
system (Becton-Dickinson, Sparks, USA) during the total study
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48 hours after blood cultures became positive. In the standard
care group, antibiotic treatment could be adjusted based on the
information that was available from Gram staining, culturing
results and results of susceptibility testing. In the intervention
group, antibiotic treatment could be adjusted based on the results
of direct MALDI-TOF MS analysis in addition to the information
that was available from Gram staining, culturing results and results
of susceptibility testing.
Ethics Statement
Informed consent was not obtained as included patients were
not subjected to extra procedures or questions. No personal
information was stored in the study database. As the intervention
of this study was purely laboratory based without involvement of
patients formal IRB review was not necessary. Samples were
collected as part of standard care and samples employed in the
analyses were de-identified before access.
Preparation of samples
Five ml of a positive blood culture broth was centrifuged at
170 g for 5 minutes. Subsequently, 3 ml of the supernatant was
centrifuged at 1500 g for 5 minutes. The pellet was resuspended in
5 ml of distilled water and centrifuged again at 1500 g for
5 minutes. 3 ml of the pellet was resuspended in 25 ml of 70%
formic acid and mixed with 25 ml of acetonitrile. After final
centrifugation at 18600 g for 2 minutes, 1 ml of the supernatant
was spotted in duplicate onto a MALDI-TOF MS MSP 96 ground
steel target plate (#224990, Bruker Daltonics, Bremen, Germany).
The spots were overlaid with 1 ml of matrix solution (a-cyano-4-
hydroxycinnamic acid, #255344, Bruker Daltonics) and air dried.
Mass spectrometry
Analyses were performed on a microflex LT mass spectrometer
(Bruker Daltonics). To identify microorganisms, raw spectra
obtained for each isolate were imported into BioTyper software,
version 2.0 (Bruker Daltonics), and analysed using default
parameter settings. Based on the results of previous studies that
showed high percentages of correct identification in isolates with
score values above 1.7 [6,7], isolates with spectral score$1.7 were
considered correctly identified.
Data collection and statistical analysis
Times of blood culture positivity were recorded by the Bactec
9240 system and identification times were extracted from the
laboratory information system. Antibiotic therapy data (including
all changes made) were collected from the hospital and intensive
care units’ information systems. Antimicrobial therapy was
considered inappropriate when isolated pathogens were resistant
to prescribed antimicrobial agents or when antibiotic therapy was
not according to the hospital guidelines. Species identification
based on the Phoenix system (Becton-Dickinson) was considered
reference standard.
All episodes were analyzed according to intention-to-treat
analysis. Primary outcome measure was the proportion of episodes
on adequate antimicrobial treatment within 24 hours. Secondary
outcome parameters included identification time, time until the
first switch in antibiotic treatment and number of switches in
therapy.
Results for continuous variables are expressed as means with
standard deviation (SD) or as median with interquartile range
(IQR) when not normally distributed, and for categorical variables
as percentages with the absolute number between parentheses.
Summary data were calculated using a Student’s t test (normal
distribution) or Mann-Whitney U test (skewed distribution) for
continuous variables and by chi-square analysis for categorical
variables. Statistical analyses were performed with SPSS version
15.0 (Windows, Chicago, USA).
Results
There were 253 episodes (218 patients) of bacteremia during the
4-month study period; 89 during the direct MALDI-TOF MS
period and 164 during the standard care period. This difference in
included episodes between both periods results from differences in
the total number of blood cultures submitted to the laboratory
Figure 1. Flowchart of bacteremia episodes included during the intervention and standard care period.
doi:10.1371/journal.pone.0032589.g001
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period) and the number of blood cultures that became positive
(136 during the intervention period vs 244 during the control
period). In addition, no direct MALDI-TOF MS was performed
on public holidays (figure 1).
Patients included in both periods were comparable with respect
to age (53.0 vs 55.0 for direct MALDI-TOF MS versus standard
care respectively, p0.37), proportion of ICU patients (20.2% vs
21.3%, p0.84), proportion of paediatric patients (22.5% vs 19.5%,
p0.77) and proportion of contaminated blood cultures (13.5% vs
11.0%, p0.56). Most blood cultures grew Gram-positive cocci
(59.7%) or Gram-negative bacilli (25.3%) (table S1). Differences in
isolated pathogens between the intervention and standard care
were not significant (p0.74).
Direct MALDI-TOF MS analysis yielded correct identification
in 56.2% of episodes (n=50) with spectral score$1.7. No reliable
identification was obtained in 39.3% (n=35) of episodes (no
MALDI-TOF identification (n=25), identification with score
value,1.7 (n=4) or identification of one species while the blood
culture yielded 2 or 3 species (n=6)). In the remaining 4.5% of
episodes, no direct MALDI-TOF MS was performed (n=4).
Of monomicrobial episodes, 63.6% was correctly identified and
of episodes caused by Gram-negative bacilli, 87.0% of all
identifications were correct (table 1 and table S2). For most
polymicrobial episodes, no reliable identification was obtained
(table 2).
Direct MALDI-TOF MS analysis resulted in a 28.8-h reduction
in the median time to species identification, from 45.2 hours (IQR
35.5–55.9) during standard care to 16.4 hours (IQR 10.3–42.9) in
the intervention period (p,0.001) (table 3). In the direct MALDI-
TOF MS group, species identification was available within
10 hours in 23.6% of episodes. Without direct MALDI-TOF
MS, in 76.2% of episodes identification was only available after
more than 35 hours after growth detection.
At the time of blood culture positivity, antimicrobial therapy
covered the pathogen(s) isolated from the blood culture in 53.0%
(n=134) of patients (MALDI-TOF MS 55.1%, conventional
51.8%) (p 0.20). In 20.9% (n=53) of patients antimicrobial
therapy was considered inappropriate and in 26.1% (n=66) of
patients blood cultures were considered contaminated or no
antimicrobial treatment had been initiated. Inappropriate therapy
most frequently occurred for Coagulase-negative staphylococci
(n=12), S. aureus (n=10), enterococci (n=8) and for Enterobac-
teriaceae considered as potential AmpC producers (n=5)
(table S3).
Twenty-four hours after blood culture positivity, proportions of
appropriate treatment were 64.0% and 75.3% in the standard care
and intervention period, respectively (p0.01) (table 4). If a reliable
MALDI-TOF MS result was obtained the proportion of
appropriate treatment after 24 hours rose to 82.0%.
Median times until the first switch in antibiotic therapy were
17.5 hours (IQR 9.8–38.8) and 24.0 hours (IQR 9.5–47.0) in the
intervention and standard care periods, respectively (p0.30)
(table 3). In 57.3% of bacteremia episodes antibiotic therapy was
not changed (intervention 55.0%, standard care 58.8%). The
number of antibiotic changes and the time till change were not
statistically significant between both study groups (data not shown).
Discussion
In this trial of 253 episodes of bloodstream infections, MALDI-
TOF MS directly performed on positive blood culture broths
reduced the time until definitive identification of bacterial species
by 28.8 hours and increased the proportion of patients on
appropriate antimicrobial therapy within 24 hours by 11.3%.
In previous studies, the clinical impact of rapid microbiology
results has been investigated by means of different interventions,
including the immediate incubation of blood cultures outside the
laboratory operation time [10], reducing turnaround time by the
use of the Microscan system (Baxter-Microscan, Sacramento,
USA) [11], more rapid reporting of culture results [12] and direct
analysis of positive blood cultures with the Vitek System
(bioMerieux, Marcy-l’Etoile, France) in combination with more
rapid reporting of culture results [13]. As a consequence of these
interventions, shorter time until the first switch in antibiotic
Table 1. Number of correct and incorrect direct MALDI-TOF MS identification in 77 monomicrobial episodes.
Gram positive cocci Gram positive bacilli Gram negative bacilli Total
Correct identification score$2.0 6 (11.8%) - 14 (60.9%) 20 (26.0%)
Correct identification 1.7#score,2.0 21 (41.2%) 2 (66.7%) 6 (26.1%) 29 (37.7%)
No reliable identification 21 (41.2%) 1 (33.3%) 2 (8.7%) 24 (31.2%)
No MALDI-TOF MS 3 (5.9%) 1 (4.3%) 4 (5.2%)
Total 51 (100%) 3 (100%) 23 (100%) 77 (100%)
doi:10.1371/journal.pone.0032589.t001
Table 2. Number of correct and incorrect direct MALDI-TOF MS identification in 12 polymicrobial episodes.
Mixed infections, 2 species Mixed infections, 3 species
Correct identification all microorganisms 1 (10%) -
Correct identification 1 of the species with score$2.0 3 (30%) -
Correct identification 1 of the species with 1.7#score,2.0 2 (20%) 1 (50%)
No reliable identification of any of the species 4 (40%) 1 (50%)
Total 10 (100%) 2 (100%)
doi:10.1371/journal.pone.0032589.t002
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lower antibiotic use [13] and lower costs [11,12] were reported.
Most of these studies examined the clinical effect of more rapid
identification in combination with rapid susceptibility testing [10–
12], and only one of these studies was restricted to blood culture
isolates [10]. Moreover, the exact time of antibiotic switching was
not recorded in all studies and different definitions of switching
were used [12,13]. In this study only the identification time was
shortened while the duration of susceptibility testing was left
unchanged. Therefore, any change in the proportion of patients
on adequate treatment can be attributed to the use of direct
MALDI-TOF MS analysis.
Contribution of microbiology results to antimicrobial manage-
ment depends on local antimicrobial policies and bacterial
ecology. This study was performed in a setting where antibiotic
resistance is infrequent, which allows species identification to be a
more powerful tool than in settings with more complex resistance
patterns. Inadequate empirical therapy occurs infrequently in our
population because of low resistance levels. For instance, there
were no bacteremia episodes with MRSA and vancomycin
resistant enterococci and empirical therapy was adequate in the
majority of patients already receiving antimicrobial treatment.
In this study antimicrobial therapy was judged inappropriate
when isolated pathogens were resistant to prescribed agents or
when antibiotic therapy was not according to the hospital
guidelines. Consequently, a few antimicrobial regimens judged
inappropriate may, although suboptimal, be effective against the
causative pathogens. In this study, direct MALDI-TOF MS
yielded correct identification in a lower proportion of episodes
compared to the results of previous studies. This might be
explained by a relatively large proportion of Gram positive and
polymicrobial infections in this study, while in other studies
polymicrobial samples have been excluded[6]. It is known that
Gram positive and polymicrobial infections are often not
accurately identified by direct MALDI-TOF MS [14]. However,
adaptations in sample processing may increase rates of correctly
identified microorganisms [7,15–17] and thereby increase clinical
impact of direct MALDI-TOF MS even further.
Limitations of this study include the fact that the study size was
too small to evaluate differences in morbidity or mortality between
the intervention group and the standard care group. In addition,
MALDI-TOF MS only provides identification without informa-
tion on antimicrobial susceptibility. This information can guide
antibiotic management better in a setting with low levels of
antibiotic resistance compared to areas with higher levels of
resistance. This may decrease generalizability of our data to
countries with higher levels of antibiotic resistance.
In conclusion, the use of direct MALDI-TOF MS on positive
blood cultures resulted in a faster identification of microorganisms
causing bloodstream infection. Routine implementation of this
Table 3. Effect of direct MALDI-TOF MS on identification time and antibiotic switching.
Direct MALDI-TOF MS (n=89) Standard care (n=164) p-value
Median identification time in hours (IQR) 16.4 (10.3–42.9) 45.2 (35.5–55.9) ,0.001
Episodes with ID time ,10 h 23.6% 0.6% ,0.001
10–35 h 44.9% 23.2% 0.001
35–50 h 16.9% 36.6% 0.001
.50 h 14.6% 39.6% ,0.001
Median time until first switch in antibiotic therapy in hours (IQR) 17.5 (9.8–38.8) 24.0 (9.5–47.0) 0.30
Number of switches 0 55.0% 58.8% 0.59
1 41.6% 34.8% 0.28
2 3.4% 6.7% 0.27
1st switch same day BC
a positive 40.0% 29.2% 0.20
1st switch 1 day after BC
a positive 30.0% 38.5% 0.47
1st switch.1 day after BC
a positive 30.0% 32.3% 0.92
ablood culture.
doi:10.1371/journal.pone.0032589.t003
Table 4. Effect of direct MALDI-TOF MS on proportion of appropriate treatment.
Direct MALDI-TOF MS Standard care
% (n) of episodes with appropriate
therapy,24 h after positive BC
a
75.3% (67)* 64.0% (105)*
% (n) of episodes with inappropriate
therapy,24 h after positive BC
a
4.5% (4)* 14.6% (24)*
% (n) of episodes without antibiotic
therapy,24 h after positive BC
a
20.2% (18) (6.7% (6) other interventions
b,
13.5% (12) contaminated BC)
21.4% (35) (4.3% (7) other interventions
b, 11.0%
(18) contaminated BC, 6.1% (10) not applicable
c)
ablood culture,
bremoval of intravenous catheters,
cpalliative care or patient died shortly after blood culture was positive.
*p value 0.01.
doi:10.1371/journal.pone.0032589.t004
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antimicrobial treatment within 24 hours. The cost effectiveness of
this procedure remains to be determined.
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